Radiofrequency ablation (RFA) is a minimally invasive local therapy for hepatocellular carcinoma (HCC). Even though RFA is considered to be a safe treatment modality, a variety of complications have been reported. Recently, we encountered a case of refractory fistula between a liver abscess and the gallbladder after RFA. A 64-year-old woman diagnosed with HCC associated with chronic hepatitis B was treated by RFA. After RFA, she experienced abdominal pain, and abdominal computed tomography (CT) revealed a liver abscess complicated by a previous treatment of HCC, she was treated with intravenous antibiotics and percutaneous abscess drainage. Follow-up abdominal CT revealed a fistula between the liver abscess and gallbladder, which was successfully treated with percutaneous transcatheter n-butyl-2-cyanoacrylate (NBCA) embolization. We herein report the rare case of a refractory fistula between a liver abscess and the gallbladder after RFA in a patient treated with NBCA embolization.
IntroductIon
Although the mainstay of hepatocellular carcinoma (HCC) therapy is surgical resection, the majority of patients are not treated by surgery because of tumor extent and poor hepatic reserve.
1 Radiofrequency ablation (RFA) is a minimally invasive local therapy that is a thermal ablation technique for achieving coagulative necrosis of HCC and has been considered a relatively safe treatment modality. 2, 3 However, RFA may cause complications, such as injury to the adjacent normal tissue related to mechanical and thermal damages. We report the case of a refractory fistula that developed between a liver abscess and the gallbladder after RFA in a patient that was successfully treated with percutaneous transcatheter nbutyl-2-cyanoacrylate (NBCA) embolization.
case report
A 64-year-old female patient presented to the hospital with the chief complaint of right upper quadrant ab dominal pain.
Five years prior, she had been diagnosed with HCC associated with chronic hepatitis B and had undergone repeated transarterial chemoembolization. Ten days prior, the patient was discharged without complications after RFA due to HCC 
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http://www.livercancer.or.kr occurred; we decided to perform embolization of the persistent fistula tract using NBCA (Histoacryl ® , B. Braun Avitum AG, Spangenberg, Germany).
NBCA and oily contrast agent Lipiodol Ultra-Fluid (Guerbert GmbH, Sulzbach, Germany) were mixed in a 1:1 ratio and injected at a volume and rate suitable for polymerization reaction to fill and seal the gallbladder, fistula tract, and remnant abscess cavity (Fig. 4) . After the embolization procedure, the percutaneous drainage catheter was withdrawn.
Seven days after the procedure, CT showed that the NBCA had sealed the remnant abscess cavity, fistula tract, and gallbladder, and tubography confirmed fistula tract occlusion through non-visualization of the cystic duct, common bile duct, and duodenum (Figs. 5, 6 ). The patient was discharged and was followed up periodically in the outpatient clinic with abdominal CT. Fistula-related complications no longer occurred, and NBCA and Lipiodol Ultra-Fluid mixtures were no longer visible on follow-up CT 2 years later.
dIscussIon
RFA is widely used as a curative treatment modality for early HCC, which has excellent treatment outcomes and low risks for procedures. The incidence rates of complications were found to be 2.4% in domestic studies and 1.5% in other studies. 4, 5 Complications include mild complications, such as fever, abdominal pain, and general weakness, which spontaneously subside over time, and serious major complications, Figure 3 . Tubography via pig tail catheter showed that the contrast dye passes through GB, cystic duct, CBD, and duodenum due to fistula formation between abscess and gallbladder. which may lead to death if they are not adequately diagnosed and treated, such as liver abscess, intraabdominal hemorrhage, hepatic infarction, bowel perforation, tumor seeding, biliary duodenal fistula, and abscess-colonic fistula. [4] [5] [6] The incidence rates of major complications in both domestic and other multicenter studies were found to be 2.4% and 4.0%, respectively. 5, 6 Among major complications, liver abscess is the most common. 5 Image-guided percutaneous drainage is the mainstay therapy, but this therapy modality often has limited effectiveness in the presence of an associated fistula.
There is no standard treatment for a liver abscess with a fistula. When only an abscess is treated without the fistula resolution, it causes recurrent infection or secondary complications. Our patient refused surgical treatment for fistula that did not respond to antibiotics and percutaneous drainage therapy. Therefore, nonsurgical treatment was considered, and the fistula was treated using NBCA, which is used to embolize the vascular lumen and fistula of extravascular structures. Percutaneous treatments of non-healing fistulas with the use of NBCA have been reported in patients with colonic-abscess, biliary-enteric, tracheoesophageal, and bronchopleural fistulae. [7] [8] [9] [10] This is the first case report of a fistula between a liver abscess and the gallbladder after RFA that was treated using percutaneous transcatheter NBCA embolization. Surgical resection may be considered for the treatment of a fistula, but the surgical risk is high when considering the patients' reduced liver function and performance status due to underlying cirrhosis and HCC. This case suggests that percutaneous NBCA embolization may be a therapeutic option for persistent fistula between a liver abscess and the gallbladder with an alternative to major surgical intervention. However, there is no large-scale study of the results of treatment including delayed complications and recurrence after percutaneous radiologic intervention using NBCA embolization in a fistula, so further studies are needed.
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